Temporal and spatial evolution of somatic chromosomal alterations: A case-cohort study of Barrett's esophagus

Cancer Prevention Research

Volumn 7, Issue 1, 2014, Pages 114-127

  Li, Xiaohong ^a,b   Galipeau, Patricia C ^a   Paulson, Thomas G ^a   Sanchez, Carissa A ^a   Arnaudo, Jessica ^a   Liu, Karen ^b   Sather, Cassandra L ^a   Kostadinov, Rumen L ^c   Odze, Robert D ^d   Kuhner, Mary K ^b   Maley, Carlo C ^e   Self, Steven G ^b   Vaughan, Thomas L ^b   Blount, Patricia L ^a,b   Reid, Brian J ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; ARTICLE; BARRETT ESOPHAGUS; CANCER GROWTH; CANCER PATIENT; CHROMOSOMAL INSTABILITY; CHROMOSOME 9P; CHROMOSOME ABERRATION; CHROMOSOME FRAGILE SITE; CHROMOSOME LOSS; COHORT ANALYSIS; CONTROLLED STUDY; COPY NUMBER VARIATION; EARLY DIAGNOSIS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOSCOPY; EVOLUTION; GENE DELETION; GENETIC VARIABILITY; GENOME; GENOMIC INSTABILITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PATIENT MONITORING; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC CHROMOSOMAL ALTERATION;

ADENOCARCINOMA; ADULT; AGED; BARRETT ESOPHAGUS; BIOPSY; CASE-CONTROL STUDIES; CHROMOSOMAL INSTABILITY; CHROMOSOME ABERRATIONS; DISEASE PROGRESSION; ENDOSCOPY; ESOPHAGEAL NEOPLASMS; FEMALE; GENOME, HUMAN; HUMANS; LONGITUDINAL STUDIES; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TIME FACTORS;

EID: 84892427011     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0289     Document Type: Article

References (66)

1. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005;97: 142-6.
2. Dubecz A, Gall I, Solymosi N, Schweigert M, Peters JH, Feith M, et al. Temporal trends in long-term survival and cure rates in esophageal cancer: a SEER database analysis. J Thorac Oncol 2012;7: 443-7.
3. Li Z, Rice TW, Liu X, Goldblum JR, Williams SJ, Rybicki LA, et al. Intramucosal esophageal adenocarcinoma: primum non nocere. J Thorac Cardiovasc Surg 2013;145:1519-24, 24e1-3.
4. Rice TW, Zuccaro G Jr., Adelstein DJ, Rybicki LA, Blackstone EH, Goldblum JR. Esophageal carcinoma: depth of tumor invasion is predictive of regional lymph node status. Ann Thorac Surg 1998;65: 787-92.
5. Prenzel KL, Holscher AH, Drebber U, Agavonova M, Gutschow CA, Bollschweiler E. Prognostic impact of nodal micrometastasis in early esophageal cancer. Eur J Surg Oncol 2012;38: 314-8.
6. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008;103: 788-97.
7. Reid BJ, Blount PL, Feng Z, Levine DS. Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia. Am J Gastroenterol 2000;95: 3089-96.
8. van Sandick JW, van Lanschot JJ, Kuiken BW, Tytgat GN, Offerhaus GJ, Obertop H. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 1998;43: 216-22.
9. Weston AP, Sharma P, Topalovski M, Richards R, Cherian R, Dixon A. Long-term follow-up of Barrett's high-grade dysplasia. Am J Gastroenterol 2000;95: 1888-93.
10. Bytzer P, Christensen PB, Damkier P, Vinding K, Seersholm N. Adenocarcinoma of the esophagus and Barrett's esophagus: a population- based study. Am J Gastroenterol 1999;94: 86-91.
11. Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 2002;122: 633-40.
12. Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 2011;365: 1375-83.
13. Schnell TG, Sontag SJ, Chejfec G, Aranha G, Metz A, O'Connell S, et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001;120: 1607-19.
14. Macdonald CE, Wicks AC, Playford RJ. Ten years' experience of screening patients with Barrett's oesophagus in a university teaching hospital. Gut 1997;41: 303-7.
15. Sikkema M, de Jonge PJ, Steyerberg EW, Kuipers EJ. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010;8:235-44; quiz e32.
16. Greaves M, Maley CC. Clonal evolution in cancer. Nature 2012;481: 306-13.
17. Reid BJ, Li X, Galipeau PC, Vaughan TL. Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer 2010;10: 87-101.
18. Jones S, Chen WD, Parmigiani G, Diehl F, Beerenwinkel N, Antal T, et al. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A 2008;105: 4283-8.
19. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010;467: 1114-7.
20. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998;396: 643-9.
21. Rajagopalan H, Nowak MA, Vogelstein B, Lengauer C. The significance of unstable chromosomes in colorectal cancer. Nat Rev Cancer 2003;3: 695-701.
22. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, et al. Tumour evolution inferred by single-cell sequencing. Nature 2011; 472: 90-4.
23. Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, et al. Punctuated evolution of prostate cancer genomes. Cell 2013; 153: 666-77.
24. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011;144: 27-40.
25. Navin N, Krasnitz A, Rodgers L, Cook K, Meth J, Kendall J, et al. Inferring tumor progression from genomic heterogeneity. Genome Res 2010;20: 68-80.
26. Dulak AM, Schumacher SE, van Lieshout J, Imamura Y, Fox C, Shim B, et al. Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res 2012;72: 4383-93.
27. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010;463: 899-905.
28. Goh XY, Rees JR, Paterson AL, Chin SF, Marioni JC, Save V, et al. Integrative analysis of array-comparative genomic hybridisation and matched gene expression profiling data reveals novel genes with prognostic significance in oesophageal adenocarcinoma. Gut 2011; 60: 1317-26.
29. Gu J, Ajani JA, Hawk ET, Ye Y, Lee JH, Bhutani MS, et al. Genomewide catalogue of chromosomal aberrations in Barrett's esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis. Cancer Prev Res 2010;3: 1176-86.
30. Li X, Galipeau PC, Sanchez CA, Blount PL, Maley CC, Arnaudo J, et al. Single nucleotide polymorphism-based genome-wide chromosome copy change, loss of heterozygosity, and aneuploidy in Barrett's esophagus neoplastic progression. Cancer Prev Res 2008;1: 413-23.
31. Agrawal N, Jiao Y, Bettegowda C, Hutfless SM, Wang Y, David S, et al. Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov 2012;2: 899-905.
32. Dulak AM, Stojanov P, Peng S, Lawrence MS, Fox C, Stewart C, et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet 2013;45: 478-86.
33. Prentice RL. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 1986;73: 1-11.
34. Levine DS, Blount PL, Rudolph RE, Reid BJ. Safety of a systematic endoscopic biopsy protocol in patients with Barrett's esophagus.AmJ Gastroenterol 2000;95: 1152-7.
35. Vaughan TL, Dong LM, Blount PL, Ayub K, Odze RD, Sanchez CA, et al. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol 2005;6: 945-52.
36. Barrett MT, Sanchez CA, Prevo LJ, Wong DJ, Galipeau PC, Paulson TG, et al. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Gen 1999;22: 106-9.
37. Galipeau PC, Li X, Blount PL, Maley CC, Sanchez CA, Odze RD, et al. NSAIDs modulate CDKN2A, TP53, and DNA content risk for future esophageal adenocarcinoma. PLoS Med 2007;4:e67.
38. Prevo LJ, Sanchez CA, Galipeau PC, Reid BJ. p53-mutant clones and field effects in Barrett's esophagus. Cancer Res 1999;59: 4784-7.
39. Rabinovitch PS, Reid BJ, Haggitt RC, Norwood TH, Rubin CE. Progression to cancer in Barrett's esophagus is associated with genomic instability. Lab Invest 1989;60: 65-71.
40. Avidan B, Sonnenberg A, Schnell TG, Chejfec G, Metz A, Sontag SJ. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol 2002; 97: 1930-6.
41. Cheng H, Bjerknes M, Amar J. Methods for the determination of epithelial cell kinetic parameters of human colonic epithelium isolated from surgical and biopsy specimens. Gastroenterology 1984; 86: 78-85.
42. Mountain JL, Cavalli-Sforza LL. Multilocus genotypes, a tree of individuals, and human evolutionary history. Am J Hum Genet 1997;61: 705-18.
43. Self SG, Prentice RL. Asymptotic distribution theory and efficiency results for case-cohort studies. Ann Stat 1988;16: 64-81.
44. Maley CC, Galipeau PC, Finley JC, Wongsurawat VJ, Li X, Sanchez CA, et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 2006;38: 468-73.
45. Merlo LM, Shah NA, Li X, Blount PL, Vaughan TL, Reid BJ, et al. A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prev Res 2010;11: 1388-97.
46. Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology 2011;140: 1084-91.
47. Corley DA, Mehtani K, Quesenberry C, Zhao W, de Boer J, Weiss NS. Impact of endoscopic surveillance on mortality from Barrett's esophagus- associated esophageal adenocarcinomas. Gastroenterology 2013;145:312-9 e1.
48. Nancarrow DJ, Handoko HY, Smithers BM, Gotley DC, Drew PA, Watson DI, et al. Genome-wide copy number analysis in esophageal adenocarcinoma using high-density single-nucleotide polymorphism arrays. Cancer Res 2008;68: 4163-72.
49. Li X, Blount PL, Vaughan TL, Reid BJ. Application of biomarkers in cancer risk management: evaluation from stochastic clonal evolutionary and dynamic system optimization points of view. PLoS Comput Biol 2011;7:e1001087.
50. Lai LA, Kostadinov R, Barrett MT, Peiffer DA, Pokholok D, Odze R, et al. Deletion at fragile sites is a common and early event in Barrett's esophagus. Mol Cancer Res 2010;8: 1084-94.
51. Nancarrow DJ, Clouston AD, Smithers BM, Gotley DC, Drew PA, Watson DI, et al. Whole genome expression array profiling highlights differences in mucosal defense genes in Barrett's esophagus and esophageal adenocarcinoma. PLoS One 2011;6:e22513.
52. Ostrowski J, Mikula M, Karczmarski J, Rubel T, Wyrwicz LS, Bragoszewski P, et al. Molecular defense mechanisms of Barrett's metaplasia estimated by an integrative genomics. J Mol Med 2007; 85: 733-43.
53. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012;486: 346-52.
54. Carter SL, Cibulskis K, Helman E, McKenna A, Shen H, Zack T, et al. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol 2012;30: 413-21.
55. Galipeau PC, Cowan DS, Sanchez CA, Barrett MT, Emond MJ, Levine DS, et al. 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc Natl Acad Sci U S A 1996;93: 7081-4.
56. Brown PO, Palmer C. The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med 2009;6: e1000114.
57. Li X, Self SG, Galipeau PC, Paulson TG, Reid BJ. Direct inference of SNP heterozygosity rates and resolution of LOH detection. PLoS Comput Biol 2007;3:e244.
58. Odze RD. What the gastroenterologist needs to know about the histology of Barrett's esophagus. Curr Opin Gastroenterol 2011;27: 389-96.
59. Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000;95: 1669-76.
60. Pavelka N, Rancati G, Li R. Dr Jekyll and Mr Hyde: role of aneuploidy in cellular adaptation and cancer. Curr Opin Cell Biol 2010;22: 809-15.
61. Gordon DJ, Resio B, Pellman D. Causes and consequences of aneuploidy in cancer. Nat Rev Genet 2012;13: 189-203.
62. Croswell JM, Ransohoff DF, Kramer BS. Principles of cancer screening: lessons from history and study design issues. Semin Oncol 2010;37: 202-15.
63. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst 2010;102: 605-13.
64. Esserman LJ, Thompson IM Jr, Reid B. Overdiagnosis and overtreatment in cancer: an opportunity for improvement. JAMA 2013; 310: 797-8.
65. Theisen J, Stein HJ, Dittler HJ, Feith M, Moebius C, Kauer WK, et al. Preoperative chemotherapy unmasks underlying Barrett's mucosa in patients with adenocarcinoma of the distal esophagus. Surg Endosc 2002;16: 671-3.
66. Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D, et al. Circos: an information aesthetic for comparative genomics. Genome Res 2009;19: 1639-45.